IK Partners agrees to exit stake in Klingel Medical Group

Klingel is a full-service provider for components and custom products for medical technology.

  • IK acquired Klingel in 2018
  • Klingel is headquartered in Pforzheim, Germany
  • IK Partners is a European private equity firm focused on investments in the Benelux, DACH, France, Nordics, and the UK

IK Partners, via IK VIII Fund, has agreed to sell its stake in Klingel Medical Group, a full-service provider for components and custom products for medical technology, to Elos Medtech.

No financial details of the transaction were disclosed.

Klingel is headquartered in Pforzheim, Germany.

IK acquired Klingel in 2018.

“One of the reasons we invested in Klingel, was the fragmented nature of this market and its consolidation potential,” said Anders Petersson, managing partner at IK and advisor to the IK VIII Fund. “With our support, the group has been able to make several exciting bolt-on acquisitions and become a consolidator in the market, which has enabled Klingel to become a leading CDMO in the MedTech sector.”

Klingel’s sales have more than trebled driven by an expansion of production technologies and the bolt-on acquisitions of GEHRING CUT, Bächler Feintech, puracon and Ruetschi, according to a release.

Elos Medtech is a development and production partner for medical devices and components, with a focus on dental and orthopaedic implants and instruments. The company has a turnover of around SKr 950 million (€82 million; $90 million). It is based in Goteborg, Sweden.

IK is a European private equity firm focused on investments in the Benelux, DACH, France, Nordics, and the UK. The firm, based in London, has raised over €14 billion of capital.